Lead investigational candidate, MBRC-101, uniquely targets EphA5 receptor tyrosine kinase, which is present in multiple cancers, including breast, non-small cell lung (NSCLC), colorectal, gastric, and pancreatic cancersNew data support potential of MBRC-101 for treatment of solid tumors including hormone receptor-po.
MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
– Oversubscribed Series B round led by TPG includes prominent group of new and existing investors, bringing total raised to-date to over $110 million– Funding supports rapid clinical development of targeted ADC therapeutics in difficult-to-treat cancers – Chris LeMasters joins as Independent Board Member, bringing 2.